Close Menu

Celmatix

The new division — called Celmatix Biosciences — will focus on women's health indications with high unmet need including reproductive disorders and menopause.

The Fertilome test, a multigene sequencing panel, assesses a number of markers that have been associated with conditions that affect fertility.

The partners plan to investigate whether a woman’s response to ovarian stimulation during IVF treatment is linked to genomic characteristics.

The firm recently won $4.5 million as well as approval for its Fertilome test from New York state, though some have questioned the test's clinical utility.

The award is one of 121 for projects in New York City this year, totaling $64.8 million.

The firm has secured NYS approval for its sequencing-based 32-gene Fertilome assay, which it originally launched in January. 

The companies will recruit and track a cohort of women to study environmental, genetic, and lifestyle factors that may contribute to fertility outcomes.

Fertility Genetics

Celmatix's Fertilome test aims to give women genetic insight into their fertility.

The company's new blood-based test is the first clinical test offering that the company will be offering at its New York-based CLIA laboratory.

They will work to accelerate the launch of Celmatix's infertility genetics tests and develop early screening tests for declining ovarian function.

The New York Times Magazine examines gender discrimination at the Salk Institute.

Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.

A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.

In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.